obesity-995x60.png
FEATURED ARTICLES
It Is Time To Require Human-Relevant Efficacy Evidence Before First-In-Human Trials
Why, when human-relevant evidence of likely efficacy can be generated before a trial begins, is it not evaluated before patients are exposed?
-
The Rise Of Chinese Biotechs And The Global CRO Question
As innovative therapies move beyond home markets, early planning across regulators and geographies helps avoid costly delays and protect trial budgets.
-
Immune Priming, Oncolytic Viruses, And The Next Phase Of Solid Tumor Immunotherapy
Can priming with oncolytic viruses be a better path to reeducating the immune system to recognize and attack cancer? Oncolytics Biotech advisor Richard Vile, Ph.D., says yes.
-
How Modern Logistics Support Belmont And HHS OIG Goals
Participant support can expand trial access, but regulatory uncertainty limits adoption. A safe harbor could enable reimbursement and compensation while protecting against coercion and undue influence.